IMUGENE LIMITED — AGM Information 2025

Jun 25, 2025

==> picture [306 x 53] intentionally omitted <==

EXTRAORDINARY GENERAL MEETING Thursday, 26 June 2025

1

Imugene is a clinical stage cancer company developing three drug products in CAR T cell therapy and oncolytic viruses

==> picture [138 x 24] intentionally omitted <==

==> picture [230 x 26] intentionally omitted <==

==> picture [212 x 27] intentionally omitted <==

==> picture [885 x 255] intentionally omitted <==

----- Start of picture text ----- azer-cel CD19 allo CAR T onCARlytics CD19 expressing virus CF33 Oncolytic VirusPhase 1b Phase 1 OASIS Trial Phase 1 VAXINIA MAST TrialOff-the-shelf drug, aka allogeneic CAR T targetingNovel virus which acts as a CD19 target in solid Novel cancer killing virusblood cancerscancersTargeting a range of late-stage solid cancers57% complete response; best overall durability at >14 Makes solid cancers visible to CD19 drugsmonths and on goingEncouraging results in bile tract cancer and durableCurrently in Phase 1 in solid cancers in combination stability of diseaseAnticipate to initiate Pivotal Phase 2/3 registrational with Blinatumomab (Approved CD19 drug in bloodtrial in CY2026 (subject to data and regulatory cancers)FDA INDapprovals) – FDA meeting expected in late 2025FDA INDFDA IND----- End of picture text -----

FDA IND

• Manufacturing: Out-Licensed azer-cel Phase 1b product to Kincell along with CAR T engineers to off-set cost and headcount

• Business and Development: Partnering/Out-licensing Opportunity is ongoing

• IR Conference Presentations: Dr. Jakob Dupont will be the keynote speaker at the Biotech Summit, E&P and Bell Potter’s Healthcare conferences

• Potential Science Conferences: Targeting AACR, ASCO, LUGANO, SNO, ASH, SITC etc.

• Cost Control: Head count reductions, prioritizing programs for value impacting studies are on-going

A S X : I M U

Thank You For Attending

17